查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918186

基因检测市场－2026-2031年预测

Hereditary Testing Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

基因检测市场预计将从 2025 年的 36.72 亿美元成长到 2031 年的 60.58 亿美元，复合年增长率为 8.7%。

基因检测市场涵盖了复杂且快速发展的分子诊断领域，专注于识别与遗传疾病、疾病易感性和药物反应相关的基因变异。该市场是精准医疗模式的核心，它将患者照护从被动治疗转变为主动风险评估和个人化管理策略。

核心临床价值与应用范围

基因检测透过分析个体的DNA提供重要的资讯。具体应用包括：检测可能导致遗传性疾病的突变（诊断性检测）、预测癌症等遗传性疾病的风险（预测性/易感性检测）以及辅助药物选择和剂量决策（药物遗传学）。其应用领域涵盖产前和新生儿筛检、肿瘤学、心臟病学、神经病学和药物治疗。基因检测的根本价值在于能够实现早期疗育、指南后续观察、为治疗方案选择提供依据，并促进家族内部的级联检测，从而改善临床疗效并优化医疗资源配置。

主要市场成长驱动因素

市场扩张是由几个强劲的协同趋势所驱动的。全球癌症发生率的上升是主要驱动因素，尤其是那些具有明确遗传倾向的癌症，例如乳癌、卵巢、大肠直肠癌和胰腺癌。在公共卫生宣传活动和专业指南的推动下，临床医生和患者对遗传性癌症综合征的认识不断提高，这刺激了对生殖系检测的需求，以指南风险管理、手术决策和生育计划。

同时，药物基因体学（PGx）与主流临床实践的融合显着拓展了其应用领域。 PGx检测越来越多地被用于指南多种治疗药物的处方，包括抗忧郁症、抗血小板药和化疗药物，并根据个体的基因组成预测疗效和不利事件风险。专家共识指南的发布和标准化检测方案的开发提高了临床可靠性，并加速了其在医疗保健系统中的应用。

技术进步，特别是次世代定序（NGS）技术的广泛应用和成本下降，是市场成长的根本驱动力。 NGS能够同时分析多个基因，甚至整个EXOME/基因组，取代了传统的单基因顺序检测。这项技术飞跃显着提高了基因检测的通量、范围和发现能力，使全面的检测组合和广泛的基因组分析更容易获取，也更具临床可行性。

政府和机构的支持也是关键驱动因素。国家公共卫生项目，新生儿筛检筛检，能够提高基因筛检的可近性，直接增加检测量。此外，卫生部门和医学协会制定法规结构和专业指南，有助于检测方法的标准化、品质保证和完善报销机制，进而使基因检测合法化并纳入标准治疗通讯协定。

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章 依疾病类型分類的基因检测市场

  • 介绍
  • 遗传性癌症检测
  • 遗传性非癌症检测

第六章 依技术分類的基因检测市场

  • 介绍
  • 细胞遗传学检测
  • 生化检测
  • 分子检测

第七章 依最终用户分類的基因检测市场

  • 介绍
  • 医院
  • 诊所
  • 其他的

第八章 各地区的基因检测市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • MedGenome
  • Myriad Genome
  • Mapmygenome
  • Invitae
  • Ambry Genetics
  • 23andMe
  • ARUP Laboratories
  • GeneDx
  • Criver
  • Medline Plus
  • Mayo Clinic

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061616013

Hereditary Testing Market is expected to rise at a 8.7% CAGR, growing from USD 3.672 billion in 2025 to USD 6.058 billion in 2031.

The hereditary testing market encompasses a sophisticated and rapidly evolving segment of molecular diagnostics focused on identifying genetic variants associated with inherited disorders, disease predisposition, and drug response. This market is central to the paradigm of precision medicine, transforming patient care from reactive treatment to proactive risk assessment and personalized management strategies.

Core Clinical Value and Application Spectrum

Hereditary testing provides critical insights by analyzing an individual's DNA to detect mutations that may be causative for genetic disorders (diagnostic testing), indicate an elevated risk for developing conditions such as hereditary cancers (predictive/predispositional testing), or inform medication selection and dosing (pharmacogenomics). Its applications span prenatal and newborn screening, oncology, cardiology, neurology, and pharmacotherapy. The fundamental value lies in enabling earlier intervention, guiding targeted surveillance, informing therapeutic choices, and facilitating cascade testing within families, thereby improving clinical outcomes and optimizing healthcare resource allocation.

Primary Market Growth Drivers

Market expansion is propelled by several powerful and synergistic trends. The rising global prevalence of cancer, particularly those with known hereditary components such as breast, ovarian, colorectal, and pancreatic cancers, is a paramount driver. Increased awareness of hereditary cancer syndromes among both clinicians and patients, fueled by public health campaigns and professional guidelines, is stimulating demand for germline testing to inform risk management, surgical decisions, and family planning.

Concurrently, the integration of pharmacogenomics (PGx) into mainstream clinical practice is creating a substantial new application segment. PGx testing is increasingly utilized to guide prescribing for a range of therapeutics, including antidepressants, antiplatelets, and chemotherapeutic agents, by predicting efficacy and adverse event risk based on an individual's genetic makeup. The publication of professional consensus guidelines and the development of standardized testing panels are lending clinical credibility and accelerating adoption across healthcare systems.

Technological advancement, particularly the widespread adoption and decreasing cost of next-generation sequencing (NGS), is the foundational enabler of market growth. NGS allows for the simultaneous analysis of multiple genes or even the entire exome/genome, replacing older, sequential single-gene tests. This technological leap has vastly increased the throughput, scope, and discovery power of hereditary testing, making comprehensive panels and broader genomic analyses more accessible and clinically feasible.

Supportive governmental and institutional initiatives are also critical catalysts. National public health programs that expand access to genetic screening-such as universal non-invasive prenatal testing (NIPT) or newborn screening expansions-directly drive test volumes. Furthermore, the development of regulatory frameworks and professional guidelines by health authorities and medical societies helps standardize testing practices, ensure quality, and bolster reimbursement pathways, thereby legitimizing and integrating genetic testing into standard care protocols.

Key Application and Technology Segments

The market is segmented by both application and technology. The oncology segment remains the largest and most dynamic, driven by the clinical utility of testing for hereditary breast and ovarian cancer (HBOC) and Lynch syndrome, among others. The pharmacogenomics segment is experiencing rapid growth as evidence accumulates and implementation barriers are addressed.

From a technological standpoint, NGS-based multi-gene panels dominate the landscape for hereditary cancer and comprehensive disorder testing. However, targeted testing methods for specific high-penetrance variants and array-based technologies for pharmacogenomics also maintain significant roles. The continuous evolution of bioinformatics pipelines for variant interpretation is a critical, albeit less visible, component of the technological ecosystem.

Geographic Landscape and Regulatory Environment

Europe represents a leading and mature market, characterized by well-established healthcare infrastructures, a high degree of technological adoption, and proactive regulatory and professional bodies that issue testing guidelines. The presence of major diagnostic companies and a supportive environment for genetic services contribute to the region's significant market share.

Globally, the market is shaped by distinct regional regulatory frameworks governing test approval, laboratory licensing, and data privacy. These variations influence the pace of new test introductions and commercial strategies. Markets with clearer reimbursement mechanisms for genetic tests typically exhibit faster adoption and more robust competition among providers.

Competitive Landscape and Strategic Evolution

The competitive landscape is diverse, including large commercial diagnostic laboratories, specialized genetic testing companies, and in-house hospital laboratories. Strategic activities are intensely focused on research and development to expand test menus, improve variant classification, and reduce turnaround times. Key players are engaged in securing regulatory clearances for their tests, publishing clinical validity and utility data in peer-reviewed journals, and forming strategic partnerships with academic medical centers, pharmaceutical companies, and health systems to integrate testing into clinical pathways.

Future Market Trajectory

The future trajectory of the hereditary testing market points toward greater integration, automation, and data-driven insights. Testing will move further into routine primary and specialty care as clinical decision support tools become more embedded in electronic health records. The application of artificial intelligence and machine learning to improve variant interpretation and risk prediction will enhance the value of genomic data.

Market growth will be sustained by the ongoing discovery of new gene-disease associations, the expansion of polygenic risk scores for common diseases, and the continuous decrease in sequencing costs. However, success will also depend on effectively addressing challenges related to equitable access, genetic counseling workforce capacity, data privacy, and the responsible communication of complex results. As a cornerstone of modern, preventative, and personalized medicine, the hereditary testing market is poised for sustained expansion, driven by irreversible advances in genomic science and a deepening understanding of the genetic basis of health and disease.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2025 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Hereditary Testing Market Segmentation

  • By Disease Type
  • Hereditary Cancer Testing
  • Hereditary Non-Cancer Testing
  • By Technology
  • Cytogenetic
  • Biochemical
  • Molecular Testing
  • By End-User
  • Hospitals
  • Clinics
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEREDITARY TESTING MARKET BY DISEASE TYPE

  • 5.1. Introduction
  • 5.2. Hereditary Cancer Testing
  • 5.3. Hereditary Non-Cancer Testing

6. HEREDITARY TESTING MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Cytogenetic
  • 6.3. Biochemical
  • 6.4. Molecular Testing

7. HEREDITARY TESTING MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. HEREDITARY TESTING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. MedGenome
  • 10.2. Myriad Genome
  • 10.3. Mapmygenome
  • 10.4. Invitae
  • 10.5. Ambry Genetics
  • 10.6. 23andMe
  • 10.7. ARUP Laboratories
  • 10.8. GeneDx
  • 10.9. Criver
  • 10.10. Medline Plus
  • 10.11. Mayo Clinic

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations